世界の希少疾病用医薬品市場動向(~2020)

◆英語タイトル:Global Orphan Drugs Market Outlook 2020
◆商品コード:RNCS60102
◆発行会社(リサーチ会社):RNCOS
◆発行日:2016年1月
◆ページ数:70
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Multi-UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、世界の希少疾病用医薬品市場について調査・分析し、市場概要、市場動向、市場展望、世界の希少疾病用医薬品市場規模、地域別市場規模、種類別市場規模、用途別市場規模、主要企業分析などの情報をお届けいたします。

・世界の希少疾病用医薬品市場:市場概要
・世界の希少疾病用医薬品市場:市場動向
・世界の希少疾病用医薬品市場:市場展望
・世界の希少疾病用医薬品市場:種類別市場規模
・世界の希少疾病用医薬品市場:用途別市場規模
・世界の希少疾病用医薬品市場:地域別市場規模
・世界の希少疾病用医薬品市場:主要企業分析

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

Orphan drugs, also called niche busters, are intended to treat patients suffering from very serious diseases for which no treatment or at least a satisfactory one, has so far been available. These diseases, often referred to as orphan diseases or rare diseases, affect only a small portion of the population. The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs. Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.

According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.

The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.

The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Orphan Drug – An Introduction
4. Drivers and Challenges
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Prevalence of Chronic Diseases
4.1.3 Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost of Orphan Drugs
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Increased Competition from Generics Industry
5. Global Orphan Drug Market – Overview
6. Market Segmentation
6.1 By Type
6.2 By Geography
6.3 By Applications
7. Current Status of Orphan Drugs in Pipeline
8. Trends and Developments
8.1 Rise in Number of Orphan Drugs for Oncology
8.2 Gene Therapy- Gaining Popularity for Rare Conditions
9. Mergers and Acquisitions
10. Regulatory Scenario
10.1 US
10.2 EU
10.3 Japan
10.4 India
10.5 China
11. Competitive Landscape
12. Key Player Analysis
12.1 Novartis
12.2 F. Hoffmann-La Roche AG
12.3 Celgene Corporation
12.4 Pfizer Inc.
12.5 Sanofi
12.6 Bristol-Myers Squibb
12.7 Johnson & Johnson
12.8 Merck & Co., Inc.
12.9 Boehringer Ingelheim GmbH
12.10 AbbVie
13. Opportunities & Recommendations
13.1 Opportunities
13.2 Recommendations

List of Figures:

Figure 5-1: Global – Orphan Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global – Orphan Drugs Market by Type (%), 2014
Figure 6-2: Global – Orphan Drugs Market by Geography (%), 2014
Figure 6-3: Global – Orphan Drugs Market by Applications (%), 2014
Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
Figure 12-1: Novartis – Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche – Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Celgene Corporation – Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Pfizer Inc – Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Sanofi – Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb – Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Johnson & Johnson – Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Merck & Co., Inc. – Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Boehringer Ingelheim GmbH – Break up of Revenue by Geographies (%), 2014
Figure 12-10: AbbVie – Break up of Revenue by Geographies (%), 2014

List of Tables:

Table 7-1: Major Orphan Drugs Pipeline
Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
Table 11-1: Global – Major Orphan Drugs Revenue (Billion US$), 2014
Table 12-1: Novartis – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: Novartis – Orphan Drugs
Table 12-3: Roche – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Roche – Orphan Drugs
Table 12-5: Celgene Corporation – Orphan Drugs
Table 12-6: Pfizer Inc – Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-7: Pfizer Inc – Orphan Drugs
Table 12-8: Sanofi – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Sanofi – Orphan Drugs
Table 12-10: Bristol Myers Squibb – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Bristol Myers Squibb – Orphan Drugs
Table 12-12: Johnson & Johnson – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-13: Johnson & Johnson – Orphan Drugs
Table 12-14: Merck & Co., Inc. – Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-15: Merck & Co., Inc. – Orphan Drugs
Table 12-16: Boehringer Ingelheim GmbH – Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-17: Boehringer Ingelheim GmbH – Orphan Drugs
Table 12-18: AbbVie – Orphan Drugs



【レポートのキーワード】

希少疾病用医薬品

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の希少疾病用医薬品市場動向(~2020)(Global Orphan Drugs Market Outlook 2020)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆